134 results on '"Jäger, Ulrich"'
Search Results
2. Characteristics of chronic lymphocytic leukemia in Japan: Comprehensive analysis of the CLLRSG-01 study
3. Author Correction: Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study
4. Daratumumab monotherapy in refractory warm autoimmune hemolytic anemia and cold agglutinin disease
5. Narcissistic dimensions and depressive symptoms in patients across mental disorders in cognitive behavioural therapy and in psychoanalytic interactional therapy in Germany: a prospective cohort study
6. Affective temperament, fatigue, and pain in cancer patients
7. Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study
8. Reliabilität und Validität des OPD-Konfliktfragebogens bei stationären Psychotherapiepatient*innen
9. Bindung als Prädiktor von Strukturveränderungen im Verlauf von stationärer Psychotherapie
10. Integrative Beratung: Grundlagen und Perspektiven für die Praxis
11. Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with r/r DLBCL: phase 1b PORTIA study results
12. Management of Cytokine Release Syndrome (CRS) and HLH
13. Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study
14. Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab
15. Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study
16. Safety and efficacy of durvalumab with R-CHOP or R2-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial
17. Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes
18. Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma
19. Lymphodepletion – an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle
20. A chimeric antigen receptor-based cellular safeguard mechanism for selective in vivo depletion of engineered T cells.
21. Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations
22. Supplementary Data Figures from A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development
23. Data from A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development
24. Supplementary Data Tables from A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development
25. CT-526 Updated Results From a Rapcabtagene Autoleucel (YTB323) Phase I Study Demonstrate Durable Efficacy and a Manageable Safety Profile in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
26. POSTER: CT-526 Updated Results From a Rapcabtagene Autoleucel (YTB323) Phase I Study Demonstrate Durable Efficacy and a Manageable Safety Profile in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
27. Risk as a pattern over time: Delineation of time‐dependent risk factors in biological, psychological, and social variables in cancer patients
28. A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development
29. First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia
30. Sustained hematologic remission after discontinuation of sutimlimab treatment in patients with cold agglutinin disease
31. Data from Deep Morphology Learning Enhances Ex Vivo Drug Profiling-Based Precision Medicine
32. Supplementary Data from Deep Morphology Learning Enhances Ex Vivo Drug Profiling-Based Precision Medicine
33. Supplementary Table 1 from In Human Visualization of Ibrutinib-Induced CLL Compartment Shift
34. Supplementary Figures and Legends from In Human Visualization of Ibrutinib-Induced CLL Compartment Shift
35. Data from In Human Visualization of Ibrutinib-Induced CLL Compartment Shift
36. Supplementary Figure from Deep Morphology Learning Enhances Ex Vivo Drug Profiling-Based Precision Medicine
37. Supplementary Table 2 from In Human Visualization of Ibrutinib-Induced CLL Compartment Shift
38. Supplementary Table 3 from In Human Visualization of Ibrutinib-Induced CLL Compartment Shift
39. Data from Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study
40. Supplementary Figure 2A from Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study
41. Supplementary Tables 1-5 from Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study
42. Supplementary Figure 1 from Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study
43. Supplementary Data from Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study
44. Supplementary Figure 3 from Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study
45. The frequency of differentiated CD3+CD27-CD28- T cells predicts response to CART cell therapy in diffuse large B-cell lymphoma
46. N‐terminal pro‐brain natriuretic peptide is a prognostic marker for response to intensive chemotherapy, early death, and overall survival in acute myeloid leukemia
47. Past, Present, and Future Outlook for Edge Isolation Processes in Highly Efficient Silicon Solar Cell Manufacturing
48. Deep Morphology Learning Enhances Ex Vivo Drug Profiling-Based Precision Medicine
49. Past, Present, and Future Outlook for Edge Isolation Processes in Highly Efficient Silicon Solar Cell Manufacturing.
50. Long-Term Host Immune Changes Following Treatment with Venetoclax Plus Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.